Zobrazeno 1 - 9
of 9
pro vyhledávání: '"James Witek"'
Autor:
David E. Bernstein, Bart Fevery, Paul Y. Kwo, Eugene R. Schiff, Rekha Sinha, M. Davis, Ronald Nahass, Jane Scott, Norman Gitlin, James Witek, R. Kalmeijer, Monika Peeters, Sergio Rojter, Peter Ruane, Guy De La Rosa, K.P. Etzkorn, Oliver Lenz, Ziad Younes
Publikováno v:
Hepatology (Baltimore, Md.)
Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients. The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder HCV genotype (GT) 1
Autor:
Christoph Sarrazin, Simone Susser, Mathieu Flinders, Henk W. Reesink, Glenn Lawyer, Stefan Zeuzem, Anne Ghys, James Witek, Veerle Van Eygen, Sandra De Meyer
Publikováno v:
Antimicrobial agents and chemotherapy, 59(5), 2746-2755. American Society for Microbiology
In treating hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections, the rapid reselection of resistance-associated variants (RAVs) is well known in patients with repeated exposure to the same class of antiviral agents. For chronic
Autor:
Annemie Buelens, Bart Fevery, James Witek, Erkki Lathouwers, Yves Wyckmans, Anne Ghys, Oliver Lenz, Alessandra Baldini, Christoph Sarrazin, Monika Peeters, M. Schlag, Bjorn Daems, Thierry Verbinnen, Sandra De Meyer
Publikováno v:
Antiviral Research. 116:10-16
Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a, and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P) and ribavirin (R). Prevalence of Q80K among G1 p
Autor:
Sandra De Meyer, Anne Ghys, James Witek, Maria Buti, Katrien Janssen, Donghan Luo, Christoph Sarrazin, I. Dierynck, Gaston Picchio, Gavin Cloherty
Publikováno v:
Journal of Clinical Microbiology. 53:1264-1269
Protease inhibitor (PI)-based response-guided triple therapies for hepatitis C virus (HCV) infection are still widely used. Noncirrhotic treatment-naive and prior relapser patients receiving telaprevir-based treatment are eligible for shorter, 24-wee
Autor:
David M. Burger, Clara T. M. M. de Kanter, Anton S M Dofferhoff, Ralph DeMasi, James Witek, Joost P.H. Drenth, Maria Buti, Sivi Ouwerkerk-Mahadevan, Stefan Zeuzem
Publikováno v:
Antiviral Therapy, 21, 2, pp. 153-9
Antiviral Therapy, 21, 153-9
Antiviral Therapy, 21(2), 153. International Medical Press Ltd
Antiviral Therapy, 21, 153-9
Antiviral Therapy, 21(2), 153. International Medical Press Ltd
Background Monitoring ribavirin concentrations during hepatitis C treatment with dual therapy can help optimize treatment response and minimize anaemia. A defined therapeutic range for ribavirin during direct-acting antiviral-based therapies is lacki
Autor:
Gianpiero, D'Offizi, Calogero, Cammà, Chiara, Taibi, Michael, Schlag, Karin, Weber, Maria, Palma, Ralph, DeMasi, Katrien, Janssen, James, Witek, Raffaella, Lionetti
Publikováno v:
The new microbiologica. 40(1)
Simeprevir plus peg-interferon/ribavirin (PR) is approved to treat chronic hepatitis C (HCV) genotype 1 (GT1) and GT4 infection. This study aimed to assess baseline and on-treatment the factors predictive of sustained virologic response 12-weeks post
Autor:
Bart Fevery, Katrien Janssen, Thierry Verbinnen, W. Jessner, S. De Meyer, James Witek, Oliver Lenz, Monika Peeters
Publikováno v:
Journal of viral hepatitis. 24(1)
Summary Simeprevir is a hepatitis C virus NS3/4A protease inhibitor. Hepatitis C virus baseline NS3/4A polymorphisms and emerging mutations were characterized in treatment-naїve and treatment-experienced genotype 4-infected patients treated with sim
Autor:
Lai, Wei, Tao, Han, Dongliang, Yang, Jeong, Heo, Jia, Shang, Jun, Cheng, Xinyue, Chen, Qing, Xie, Ju-Hyun, Kim, Ronald, Kalmeijer, Sivi, Ouwerkerk-Mahadevan, Eva, Hoeben, Oliver, Lenz, Thierry, Verbinnen, Rekha, Sinha, MengChun, Li, Jane, Scott, Monika, Peeters, James, Witek
Publikováno v:
Journal of gastroenterology and hepatology. 31(5)
Approximately one-third of patients with hepatitis C virus (HCV) genotype (GT) 1 infection live in East Asia. This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha-2a and ribavirin (PR) i
Autor:
Ewa Janczewska, Yves Horsmans, Stefan Zeuzem, Maria Buti, Sandra De Meyer, Mario Rizzetto, Christophe Hézode, Donghan Luo, James Witek, Kosh Agarwal, Robert S. Brown, Ralph J De Masi, William Sievert, L. Nyberg, Raymundo Paraná, Kirk Bertelsen
Publikováno v:
Gastroenterology. 146:744-753.e3
Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Metho